UPMC Hillman Cancer Center | Strategic Alliance Partners

February 01, 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

January 17, 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the data from DESTINY-Breast03 with trastuzumab deruxtecan vs T-DM1 for patients with metastatic HER2-positive breast cancer, as well as how the findings set the field up to improve outcomes for patients with brain metastases.

January 14, 2022

Robert L. Ferris, MD, PhD, discusses the current standard of care for patients with head and neck cancer, the role of HPV in treatment decisions, and the need to personalize therapy for patients.

January 12, 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

January 03, 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate enobosarm in estrogen receptor–positive, androgen receptor–positive metastatic breast cancer, prior data observed with the agent, and the unmet needs positive results of the ARTEST trial could potentially fulfill.

December 23, 2021

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate HER2-directed bispecific antibodies in HER2-positive breast cancer, the emergence of zanidatamab as a potential treatment strategy, and the unmet medical need the agent could fill in this disease.

December 01, 2021

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma. 

November 06, 2021

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

November 01, 2021

Adjuvant pembrolizumab continued to showcase improved relapse-free survival over placebo in patients with resected high-risk stage II melanoma with 6 months of additional follow-up.

October 29, 2021

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

October 28, 2021

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer. 

October 25, 2021

Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.

October 22, 2021

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

October 22, 2021

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

July 19, 2021

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

January 22, 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

January 20, 2021

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

January 19, 2021

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

January 13, 2021

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

January 08, 2021

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.